BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick(Broad Institute), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Devarati Mitra(Brigham and Women's Hospital), Gëorge F. Murphy(Brigham and Women's Hospital), Keith T. Flaherty(Cancer Research Center), Alexandria P. Cogdill(University of Pennsylvania), Patrick Hwu(Moffitt Cancer Center), Willem W. Overwijk(Weatherford College), Donald P. Lawrence(Massachusetts General Hospital), Gregory Lizée(The University of Texas MD Anderson Cancer Center), Chengwen Liu(Hunan Normal University), Weiyi Peng(University of Houston), Zachary A. Cooper(AstraZeneca (Singapore)), David E. Fisher(Massachusetts General Hospital), Cecilia Lezcano(Memorial Sloan Kettering Cancer Center), Lindsay P. Newton(Brigham and Women's Hospital), F. Stephen Hodi(Harvard University), Cristina R. Ferrone(Brigham and Women's Hospital), Ryan J. Sullivan(Dana-Farber Cancer Institute), Andrea Boni(Brigham and Women's Hospital), Adriano Piris(Brigham and Women's Hospital)
Cited by 938
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k